Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alogliptin + Insulin in Japanese T2DM
NCT01521962Phase 3Completed
- Sponsor
- Takeda
- Start
- Feb 2012
- Primary completion
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Alogliptin + Insulin with Placebo + Insulin (2 arms). Primary endpoint: Change in glycosylated hemoglobin (HbA1c) at 12 weeks. Started Feb 2012; status: completed.
02
Drugs
alogliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01521962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01521962.